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The article in this issue of the Journal of Bone and MineralResearch by Farr and colleagues(1) highlights how clinical
technologies enable our ability to identify biomechanical
mechanisms contributing tomusculoskeletal health and disease.
Given that fractures are a mechanical event, establishing
biomechanical mechanisms is as important as establishing
molecular mechanisms to advance our understanding of how a
disease condition ultimately leads to increased risk of fracturing.
As noted by Farr and colleagues,(1) many investigators
consider the increased fracture risk of type II diabetic (T2D)
patients to be a conundrum, given that these individuals tend to
show normal or higher bone mineral density (BMD). This would
be considered a conundrum if one believes there is only a single
pathway leading to increased risk of fracturing. However, we now
know that reduced fracture resistance can arise through many
different pathways (Fig. 1). Themost familiar pathway to reduced
strength is through low bone mass resulting from an imbalance
between bone resorption and formation. However, there are
pathways that are less well recognized but equally important,
and these come through alterations in bone morphology (eg,
neck shaft angle, cortical thickness, trabecular bone volume
fraction [BV/TV], trabecular connectivity) or tissue‐level mechan-
ical properties (eg, strength, brittleness, toughness, fatigability).
BMD will continue to be an important screening tool for fracture
risk. However, it is too much to ask that any one technology
capture all biological and biomechanical pathways leading to
fracture risk. As such, it is important to continue developing new
tools and scientiﬁc approaches that advance our ability to
differentially diagnose fracture risk on an individualized basis.
The systematic evaluation of morphological and tissue‐level
mechanical properties presented by Farr and colleagues(1) allows
for a more precise and expanded deﬁnition of fracture risk.
Differentiating among these pathways is critical for developing
the treatment options needed to best improve bone strength for
a particular disease condition. For example, some individuals
may fracture because of excessive bone loss leading to
measurable decreases in bone strength, whereas other individu-
als may fracture because changes in the extracellular matrix lead
to decreases in tissue‐level toughness; these individuals would
need to be differentially diagnosed and treated: one to slow
bone loss and the other to improve tissue‐quality. As a ﬁeld, we
have not yet developed the tools and scientiﬁc background to
differentially diagnose and treat individuals. However, the article
by Farr and colleagues(1) certainly moves the concept of
personalized medicine one step forward.
Farr and colleagues(1) studied 30 postmenopausal womenwho
had T2D for 10 or more years and 30 age‐matched postmeno-
pausal nondiabetic controls. The study cohort showed no
difference in BMD at the hip, wrist, and spine, and no difference
in fracturehistory. They found substantial changes (32% to38%) in
corticalporosityat thedistal radius, consistentwithother studies.(2)
However, the study by Farr and colleagues(1) was not powered to
detect a difference in this particular parameter, which is also a
major contributor to tissue‐level mechanical strength.(3) They
found no deleterious changes in bonemorphology, but did ﬁnd a
10.5% change (adjusted for body mass index [BMI]) in tissue‐level
mechanical properties. Thus, by systematically evaluatingmultiple
imaging and materials testing modalities, they were able to arrive
at a biomechanical mechanism explaining why individuals with
T2D may be at increased risk of fracturing. For T2D, the
biomechanical mechanism is thought to be a consequence of
reduced tissue toughness resulting from changes in collagen
cross‐linking.(4) The in vivo results of Farr and colleagues(1) thus
conﬁrmed prior animal and ex vivo human research showing that
T2D is indeed associated with matrix‐level alterations that appear
to make the bone more damageable and brittle.
Farr and colleagues(1) reported changes in a parameter called
bone material strength (BMS), which is the name given to the
outcome measure by the manufacturer of the in vivo micro-
indentation device. This outcome measure requires some
clariﬁcation, because the BMS parameter seems to be more
related to tissue toughness rather than tissue strength, as
measured through traditional mechanical testing procedures.(5)
The device used by Farr and colleagues(1) (OsteoProbe) and its
predecessor (BioDent), both marketed by ActiveLife Scientiﬁc,
Inc. (Santa Barbara, CA, USA), were designed to assess cracking of
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the matrix based on the premise that variation in the separation
of mineralized collagen ﬁbrils contributes to crack initiation and
bone toughness.(6) BMS is a measure of how the indentation
depth of the indenter tip compares to that of plastic. The system
measures the indentation depth after a 40‐N load and then
converts this measure to BMS, which is 100 times the average
indentation distance increase from the impact into a calibration
phantom made of polymethylmethacrylate (PMMA) divided by
the indentation increase from the impact into the bone sample.
In other words, if a person has a BMS value of 100, their bone has
the same resistance to indentation as PMMA. PMMA has a
Young’s modulus of elasticity of 1.8 to 3.1 GPa and a fracture
strength of 48 to 76 MPa (http://www.engineeringtoolbox.com/
young‐modulus‐d_417.html), which are much lower than the
Young’s modulus (15 to 20 GPa) and strength of bone (205 MPa
in compression).(7) As such, it is important to recognize that the
parameter provided by themanufacturer does not appear to be a
measure of bone tissue strength.
The device measures the resistance to penetration, which
depends on how the bone gives way, or cracks, beneath the
indenter tip. This may help explain why the measurements
generated by the predecessor device (BioDent) tend to correlate
with bone toughness.(8) As far as we are aware, similar validation
studies have not yet been performed using the OsteoProbe and
so it is unclear if the outcome measure of the OsteoProbe will
also correlate with toughness. Nevertheless, it is important to
clarify that tissue‐level strength is a different mechanical
property than tissue‐level toughness. Just as we have to be
precise in the deﬁnitions used in biology (eg, osteoblasts and
osteoclasts are both cells, but they comprise very different cell
populations), we also have to be precise in our deﬁnition of
mechanical properties. Tissue strength and toughness are both
mechanical properties, but they mean different things, and
changes in each property can be differentially related to the
underlying biology in ways that are clinically meaningful. This
devicemeasures cracking of primary lamellar bone tissue located
at the periosteal surface of the tibia. This measure does not take
into account the bone microstructure (osteons, lamellae, cement
lines, porosity, etc.), which also contributes to bone toughness.(9)
As such, this device may be able to identify disease conditions
that have a matrix‐level defect, but may be more limited in its
ability to detect defects arising at higher levels of microstructure.
Changes in the outcome properties from the predecessor device
have been reported for atypical fractures.(10)
Although Farr and colleagues(1) refer to prior studies
conducted with the Biodent, much work remains to be done
to determine whether the outcome measures of the two devices
are comparable. It is important to note that the indentation
distance increase (IDI) of theOsteoProbe results from a single load
application, measured as the distance between the impact load
(10 N¼ 2.25 lbs) and the peak load (40 N¼ 9 lbs). This is different
from the IDI of the predecessor device (BioDent), which is a
measure of the distance between the end of the ﬁrst loading cycle
and the end of the 20th load cycle, where each cycle consists of a
10‐N peak load.(11) Because the BioDent and OsteoProbe use
different loading proﬁles, it remains to be determined if the
outcomes of the two devices are comparable. For the BioDent,
the loading parameters are more similar to a creep test or a low‐
cycle fatigue test. For the OsteoProbe, the loading parameters are
more like a microhardness test or a monotonic test. Thus, both
loadmagnitude and the number of load cycles differ between the
two devices. Although some readers may not appreciate the
Fig. 1. Examples of different biomechanical pathways (mechanisms) leading to the reduced fracture resistance of aging bone relative to applied loads.
Most investigators are familiar with the low bonemass path (bold). The article by Farr and colleagues(1) highlights the existence of other known paths (eg,
diet! cross‐link! reduced toughness; dashed arrows) that also compromise fracture resistance andwhichmay help explain the increased fracture risk of
T2D patients.
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subtlety in this comment, it should be noted that engineering
tests are conducted with precision for a reason, just as molecular
biologists use speciﬁc promoters in conditional knockout
experiments to differentially perturb the system biologically.
The details in load magnitude, loading mode, loading rate, cycle
number, etc., differentiate one engineering test from another and
each test provides unique insight into the material behavior of
bone. Thus, comparing the results of the OsteoProbe to that of
the BioDent should be done with caution, if at all. Thus, it remains
unclear if extrapolating the 11.7% difference between T2D and
controls measured with the OsteoProbe by Farr and colleagues(1)
to a 33.4% change in toughness, based on prior work by others
using the BioDent, was appropriate. Much basic science work
remains to be conducted to fully understand what this device is
measuring and how to interpret the changes in indentation depth
in the context of disease.
Because the microindentation device is an invasive technolo-
gy, extreme caution is warranted for the general use of this
device as a screening tool for bone disease. Although no adverse
consequences were reported by Farr and colleagues,(1) it will be
important to document these when they do occur. Farr et al.
conducted the microindentation tests in a circular pattern
(personal communication) so the microcracks were not located
close together, limiting their potential interactions. However, if
the OsteoProbe is used inappropriately whereby multiple
microcracks are placed too close together, this may adversely
affect whole‐bone strength in some patients given that the
anterior tibial midshaft is generally loaded in tension and is a site
where stress fractures occasionally occur.(12) It is also important
to be aware that standardization of the sampling site is critical,
because bone properties vary widely along the length of the
tibia.(13) Small variations in the anatomical placement of the
device could not only detrimentally damage the bone, but could
also lead to increased interindividual variation and compromise
the ability to identify a disease effect. Further, tissue‐level
mechanical properties also vary naturally relative to bone
robustness.(13) These factors should be taken into consideration
when conducting these tests. Farr and colleagues(1) standardized
the location of their tests and consequently were able to detect a
11.7% (unadjusted) difference between diabetic and nondiabetic
bone tissue. This article thus conﬁrms prior cadaveric and animal
research showing that an important factor contributing to
increased fracture incidence in diabetic bone involves changes in
the extracellular matrix that may lead to reduced tissue
toughness. As the number of individuals with T2D steadily
increases and the treatment of the primary disease for these
individuals steadily improves, it will be important to address
secondary effects of the disease such as fracture risk to develop
treatments that target thematrix‐level defect in order to improve
the overall health of these individuals.
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